Institute for Wealth Management LLC. Sells 223 Shares of Danaher Co. (NYSE:DHR)

Institute for Wealth Management LLC. trimmed its holdings in shares of Danaher Co. (NYSE:DHR) by 6.3% in the 4th quarter, HoldingsChannel.com reports. The institutional investor owned 3,304 shares of the conglomerate’s stock after selling 223 shares during the quarter. Institute for Wealth Management LLC.’s holdings in Danaher were worth $758,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also modified their holdings of the company. FMR LLC boosted its position in shares of Danaher by 15.8% in the third quarter. FMR LLC now owns 23,617,424 shares of the conglomerate’s stock worth $6,566,116,000 after purchasing an additional 3,217,631 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its holdings in shares of Danaher by 3.0% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 5,097,986 shares of the conglomerate’s stock worth $1,417,342,000 after buying an additional 148,251 shares in the last quarter. Fisher Asset Management LLC lifted its holdings in shares of Danaher by 2.6% in the third quarter. Fisher Asset Management LLC now owns 4,552,640 shares of the conglomerate’s stock worth $1,265,725,000 after buying an additional 116,299 shares in the last quarter. Massachusetts Financial Services Co. MA lifted its holdings in shares of Danaher by 17.6% in the third quarter. Massachusetts Financial Services Co. MA now owns 3,582,982 shares of the conglomerate’s stock worth $996,141,000 after buying an additional 535,254 shares in the last quarter. Finally, Montrusco Bolton Investments Inc. lifted its holdings in shares of Danaher by 0.6% in the fourth quarter. Montrusco Bolton Investments Inc. now owns 1,715,826 shares of the conglomerate’s stock worth $382,936,000 after buying an additional 9,942 shares in the last quarter. 79.05% of the stock is currently owned by institutional investors.

Danaher Trading Down 0.2 %

NYSE DHR opened at $222.56 on Friday. The company’s 50-day moving average price is $235.66 and its 200-day moving average price is $253.24. The company has a current ratio of 1.37, a quick ratio of 1.01 and a debt-to-equity ratio of 0.32. The stock has a market cap of $160.75 billion, a PE ratio of 42.15, a PEG ratio of 4.22 and a beta of 0.83. Danaher Co. has a 12 month low of $221.34 and a 12 month high of $281.70.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Wednesday, January 29th. The conglomerate reported $2.14 EPS for the quarter, hitting analysts’ consensus estimates of $2.14. Danaher had a net margin of 16.33% and a return on equity of 10.72%. During the same period in the previous year, the firm earned $2.09 EPS. Equities research analysts forecast that Danaher Co. will post 8.15 earnings per share for the current year.

Danaher Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Friday, January 31st. Shareholders of record on Friday, December 27th were issued a dividend of $0.27 per share. This represents a $1.08 annualized dividend and a yield of 0.49%. The ex-dividend date was Friday, December 27th. Danaher’s payout ratio is 20.45%.

Insiders Place Their Bets

In other Danaher news, SVP Brian W. Ellis sold 5,700 shares of the stock in a transaction dated Thursday, January 30th. The shares were sold at an average price of $224.13, for a total transaction of $1,277,541.00. Following the transaction, the senior vice president now directly owns 20,230 shares in the company, valued at $4,534,149.90. This represents a 21.98 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 11.10% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently commented on DHR. Barclays lowered their target price on shares of Danaher from $275.00 to $240.00 and set an “equal weight” rating on the stock in a report on Thursday. Guggenheim started coverage on shares of Danaher in a report on Thursday, December 19th. They issued a “buy” rating and a $275.00 target price on the stock. Raymond James decreased their price target on shares of Danaher from $300.00 to $275.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 21st. Wolfe Research raised shares of Danaher from a “peer perform” rating to an “outperform” rating and set a $285.00 price target on the stock in a research note on Thursday, October 31st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $277.00 price target (down previously from $299.00) on shares of Danaher in a research note on Thursday. Six investment analysts have rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat, Danaher currently has an average rating of “Moderate Buy” and an average price target of $278.00.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.